Protara Therapeutics (TARA) Stock: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$3.82
0.03 (0.79%)
▲
5d:
-3.78%
30d:
-1.8%
90d:
+4.66%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TARA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TARA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $3.82, which is considered oversold relative to its 30-day fair value range of $3.85 to $4.02.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is currently testing key support at $3.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.71 (+573.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is currently testing key support at $3.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.71 (+573.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.85 -
$4.02
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 573.1% below Wall St target ($25.71)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.85 -
$4.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.72
Resistance Level
$4.00
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.26
Wall Street Target
$25.71
(+573.1%)
Share & Embed Analysis
Last updated: September 13, 2026 2:39 AM ET
Data refreshes hourly during market hours. Next update: 3:39 AM
Data refreshes hourly during market hours. Next update: 3:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Jacqueline Zummo
SELL
22598 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
